NCT06433765View on ClinicalTrials.gov

A Study Evaluating the Effect of BRIUMVI® (Ublituximab) on Pregnancy and Infant Outcomes in Participants With Multiple Sclerosis (MS)

RecruitingOBSERVATIONAL
Enrollment

728

Participants

Timeline

Start Date

June 1, 2024

Primary Completion Date

March 31, 2035

Study Completion Date

March 31, 2035

Conditions
Multiple Sclerosis
Interventions
OTHER

No intervention

No intervention

Trial Locations (1)

28401-3331

RECRUITING

BRIUMVI® Pregnancy Registry Virtual Research Coordination Center, Wilmington

All Listed Sponsors
lead

TG Therapeutics, Inc.

INDUSTRY

NCT06433765 - A Study Evaluating the Effect of BRIUMVI® (Ublituximab) on Pregnancy and Infant Outcomes in Participants With Multiple Sclerosis (MS) | Biotech Hunter | Biotech Hunter